ミニ脂肪吸引法を用いたヒト皮下脂肪組織サンプリング

Executive Industry Relevance

This minimally invasive adipose tissue sampling technique enables repeated tissue collection from human participants, supporting longitudinal metabolic studies and target validation in obesity and diabetes research. By providing access to disease-relevant human tissue without surgical intervention, it reduces reliance on animal models and improves translational confidence in preclinical target de-risking. The method supports assay development and biomarker discovery pipelines by supplying consistent, quantifiable samples for mechanistic analysis.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables direct interrogation of human adipose tissue biology for target hypothesis testing and pathway clarification.
• Operational Value: Supports repeated sampling within 24 hours, facilitating before-after intervention studies to assess target engagement and pharmacological response.
• Predictive Value: Provides human-relevant data to de-risk targets early in discovery by linking molecular changes to metabolic function.

Screening & Assay Development

• Scientific Value: Delivers quantifiable tissue yields (~200 mg per biopsy) suitable for biochemical, enzymatic, and omics analyses.
• Operational Value: Standardized, reproducible procedure with minimal participant downtime enables high-throughput sample collection for assay validation.
• Assay Readiness: Generates consistent samples for screening compound effects on lipid metabolism, inflammatory signaling, and adipokine secretion.

Translational & Preclinical Research

• Translational Continuity: Bridges in vitro findings to human physiology by providing disease-relevant tissue from target populations.
• Biomarker Alignment: Enables measurement of translational biomarkers (e.g., lipid content, enzyme activity) directly from sampled tissue to support go/no-go decisions.
• Risk-Adjusted Advancement: Supports preclinical-to-clinical transition by validating target modulation in human tissue prior to costly clinical trials.

Pipeline & Workflow Integration

The technique integrates into early discovery workflows by supplying human tissue for target validation, progressing to assay development for compound screening, and enabling translational validation in preclinical models through biomarker continuity.

• Discovery Biology: Supports hypothesis-driven interrogation of adipose tissue pathways and target validation in metabolic disease models.
• Screening: Provides standardized, reproducible tissue samples for assessing compound effects on adipocyte function and metabolic signaling.
• Analytics: Enables quantitative readouts such as lipid accumulation, gene expression, and protein activity to compare experimental conditions.
• Translational Research: Connects in vitro findings to human tissue responses via measurable biomarkers like adipokine release and metabolic flux.
• Enterprise Reuse: Establishes a reusable tissue acquisition capability across metabolic, inflammatory, and endocrine discovery programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by generating human tissue data that reduces mechanistic ambiguity in target validation.
• Operational Value: Ensures standardization, reproducibility, and scalability through aseptic technique and minimal training requirements.
• Strategic Value: Improves go/no-go decision-making by providing early human tissue evidence, reducing late-stage biological risk and capital inefficiency.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on human adipose tissue response data.

Implementation Considerations

• Requires training in aseptic technique and local anesthetic administration by qualified personnel.
• Needs access to sterile surgical supplies, liposuction needles, syringes, and biosafety waste disposal.
• Demands cross-team standardization between research, clinical, and laboratory staff for consistent sample handling.
• Requires adaptation considerations when sampling from different adipose depots or participant populations (e.g., obese, diabetic).
• Limited by participant comfort and tissue yield variability; not suitable for studies requiring large tissue masses (>1g per session).

Biopharma FAQs